New therapies for type 2 diabetes based on glucagon-like peptide 1.
Publication
, Journal Article
Salehi, M; D'Alessio, DA
Published in: Cleve Clin J Med
April 2006
Cells in the gastrointestinal tract secrete several hormones that stimulate insulin secretion, one of which is glucagon-like peptide (GLP-1). Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes. One such compound, exenatide (Byetta), has recently become available, and others are in clinical development.
Duke Scholars
Published In
Cleve Clin J Med
DOI
ISSN
0891-1150
Publication Date
April 2006
Volume
73
Issue
4
Start / End Page
382 / 389
Location
United States
Related Subject Headings
- Hypoglycemic Agents
- Humans
- Glucagon-Like Peptide 1
- General & Internal Medicine
- Diabetes Mellitus, Type 2
- 32 Biomedical and clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Salehi, M., & D’Alessio, D. A. (2006). New therapies for type 2 diabetes based on glucagon-like peptide 1. Cleve Clin J Med, 73(4), 382–389. https://doi.org/10.3949/ccjm.73.4.382
Salehi, Marzieh, and David A. D’Alessio. “New therapies for type 2 diabetes based on glucagon-like peptide 1.” Cleve Clin J Med 73, no. 4 (April 2006): 382–89. https://doi.org/10.3949/ccjm.73.4.382.
Salehi M, D’Alessio DA. New therapies for type 2 diabetes based on glucagon-like peptide 1. Cleve Clin J Med. 2006 Apr;73(4):382–9.
Salehi, Marzieh, and David A. D’Alessio. “New therapies for type 2 diabetes based on glucagon-like peptide 1.” Cleve Clin J Med, vol. 73, no. 4, Apr. 2006, pp. 382–89. Pubmed, doi:10.3949/ccjm.73.4.382.
Salehi M, D’Alessio DA. New therapies for type 2 diabetes based on glucagon-like peptide 1. Cleve Clin J Med. 2006 Apr;73(4):382–389.
Published In
Cleve Clin J Med
DOI
ISSN
0891-1150
Publication Date
April 2006
Volume
73
Issue
4
Start / End Page
382 / 389
Location
United States
Related Subject Headings
- Hypoglycemic Agents
- Humans
- Glucagon-Like Peptide 1
- General & Internal Medicine
- Diabetes Mellitus, Type 2
- 32 Biomedical and clinical sciences